SCHEMBL16626673

SCHEMBL16626673

CNCc1cn(S(=O)(=O)c2cccnc2)c2cc(Nc3ccc(OC)cc3F)ccc12

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 11/20 0.43
NAMPT P43490 2/20 0.39
FBP1 P09467 1/20 0.39
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
DRD2 P14416 2/20 0.37
HTR1A P08908 1/20 0.37
HTR1D P28221 1/20 0.37
HTR1B P28222 1/20 0.37
HTR1E P28566 1/20 0.37
HTR1F P30939 1/20 0.37
HTR7 P34969 1/20 0.37
DRD3 P35462 1/20 0.37
PIK3CG P48736 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16618737 0.99 HTR6 (0.42) HTR6NAMPTFBP1CHRNB4CHRNA3
SCHEMBL16626442 0.91 LMNA (0.38) HTR6NAMPT
SCHEMBL17971524 0.91 HTR6 (0.43) HTR6NAMPTFBP1CHRNB4CHRNA3
SCHEMBL17971523 0.91 HTR6 (0.43) HTR6NAMPTFBP1CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL16619106 0.91 LMNA (0.38) HTR6NAMPT
SCHEMBL17971526 0.90 FBP1 (0.44) HTR6FBP1CHRNB4CHRNA3KEAP1
Hydrochloric Acid SCHEMBL16618805 0.90 HTR6 (0.43) HTR6NAMPTFBP1CHRNB4CHRNA3
SCHEMBL16626449 0.90 HTR6 (0.40) HTR6NAMPTCHRNB4CHRNA3KEAP1
SCHEMBL17971520 0.90 POLB (0.42) HTR6NAMPT
SCHEMBL17971525 0.90 HTR6 (0.41) HTR6FBP1CHRNB4CHRNA3KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885NAMPT 1610/4885FBP1 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.